June 14, 2025
MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly “minimal”) residual disease (MRD). Once confined […]
June 13, 2025
MILAN — Immune-based treatments continue to fall short in myelodysplastic syndromes (MDS). Now, experts from the European Hematology Association’s (EHA) Specialized Working Group on MDS here […]
June 13, 2025
The FDA has approved a before and after surgery regimen for pembrolizumab to improve outcomes in resectable locally-advanced head and neck squamous cell carcinoma (HNSCC). Specifically, […]
June 13, 2025
TOPLINE: In a first in-human study, KITE-363, an anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy, showed high rates of response in patients with highly refractory large […]
June 13, 2025
The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin formulation is meant to be […]
June 12, 2025
MILAN — Conditions like leukemia and myelodysplastic syndromes become more prevalent with age, but older patients often present with multiple comorbidities, greater physical and cognitive frailty, […]
June 12, 2025
CHICAGO — Prostate-specific antigen (PSA) levels could help guide treatment decisions for patients with metastatic hormone-sensitive prostate cancer, according to real-world findings from the IRONMAN study. […]
June 12, 2025
CHICAGO — Acute lymphoblastic leukemia (ALL) remains challenging to treat in older adult patients due to biological factors and poor treatment tolerance. But a variety of […]
June 11, 2025
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of […]